Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karel Chroust is active.

Publication


Featured researches published by Karel Chroust.


Pacing and Clinical Electrophysiology | 2006

The homozygous KCNQ1 gene mutation associated with recessive Romano-Ward syndrome.

Tomas Novotny; Jitka Kadlecová; Jan Janousek; Renata Gaillyová; Alexandra Bittnerová; Alena Floriánová; Martina Šišáková; Ondrej Toman; Karel Chroust; Ivo Papoušek; Jindrich Spinar

In a 7‐year‐old boy with normal hearing suffering from repeated syncope an extremely prolonged QTc interval (up to 700 ms) was found. The mother was completely asymptomatic and the father had an intermittently borderline QTc interval (maximum 470 ms) but no symptoms. In the proband a mutation analysis of KCNQ1 gene revealed a homozygous 1893insC mutation. The parents were heterozygous for this mutation. There was no consanguineous marriage in the family. The clinical relevance of these findings is that apparently normal individuals may have a latent reduction of repolarizing currents, a “reduced repolarization reserve,” because they are carriers of latent ion channel genes mutations.


Cancer Genetics and Cytogenetics | 2009

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.

Milena Holzerova; Edgar Faber; Jitka Veselovska; Helena Urbankova; Jana Balcarkova; Šárka Rožmanová; Jaroslava Voglová; Jan Mužík; Karel Chroust; Karel Indrak; Marie Jarosova

Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. The most frequent additional changes were deletions on the der(9q) (8 of 23), trisomy 8 (3 of 23), and an extra copy of the Ph chromosome (2 of 23). Five patients had a complex karyotype. At the latest follow-up, 49 of the 72 patients (68%) were alive, including 15 of the 23 patients with additional CAs (65%). Median follow-up was 6.6 years; median duration of IM treatment was 4.4 years. In all, 35 of the 49 patients with Ph only (71%) and 10 of the 23 patients with additional CAs (43%) achieved complete cytogenetic response. All patients with deletion on der(9q) achieved complete cytogenetic response. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.


Mutation Research-genetic Toxicology and Environmental Mutagenesis | 2001

Activation or detoxification of mutagenic and carcinogenic compounds in transgenic Drosophila expressing human glutathione S-transferase

Karel Chroust; Trevor Jowett; Mustafa F Farid-Wajidi; Jun-Yong Huang; Rysková M; Roland Wolf; Ivan Holoubek

Sensitivity of transgenic Drosophila melanogaster with expression of a human gene encoding the glutathione S-transferase alpha subunit (GSTA1-1) to 1,2:5,6-dibenzanthracene (DBA) and 1,2-dichloroethane (DCE) was investigated in the somatic mutation and recombination test (SMART). We performed the same assay in control transgenic flies expressing the bacterial lacZ gene. Three types of transgenic Drosophila strains carrying GSTA1-1 were used: two transgenic strains homozygous for the second chromosome with a single-copy transgene insertion and one strain with two transgene insertions. Larvae carrying the lacZ gene were significantly more sensitive to genotoxic effects of DBA than those carrying three copies of the GSTA1-1 gene. The larvae with lacZ expression showed significantly lower sensitivity to DCE compared with those expressing GSTA1-1. Finally, a pretreatment with buthionine-sulphoximine (BSO) in experiment with DCE significantly decreased the frequency of mutation events in larvae with three GSTA1-1 copies in comparison with others.


Alzheimers & Dementia | 2010

Epidemiology of cognitive impairment and depressive symptoms in patients with Parkinson's disease

Irena Rektorová; Martin Bareš; Robert Jech; Katerina Farnikova; Ivan Rektor; Jan Roth; Evzen Ruzicka; Petr Kanovsky; Karel Chroust; Tomáš Pavlík

P1-053 EPIDEMIOLOGY OF COGNITIVE IMPAIRMENT AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH PARKINSON’S DISEASE Irena Rektorova, Martin Bares, Robert Jech, Katerina Farnikova, Ivan Rektor, Jan Roth, Evzen Ruzicka, Petr Kanovsky, Karel Chroust, Tomas Pavlik, 1st Department of Neurology, Masaryk University and St Anne’s Hospital, Brno, Czech Republic; Department of Neurology, 1st Medical Faculty Charles University, Prague, Czech Republic; Department of Neurology, Medical Faculty Palacky University, Olomouc, Czech Republic; Institute for Biomedical Analysis, Masaryk University, Brno, Czech Republic. Contact e-mail: [email protected]


Clinical and Experimental Rheumatology | 2009

Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.

Karel Pavelka; Šárka Forejtová; Jiří Štolfa; Karel Chroust; Lucie Burešová; Heřman Mann; Jiří Vencovský


Folia Biologica | 1997

Drosophila melanogaster, Vicia faba and Arabidopsis thaliana short-term bioassays in genotoxicity evaluation of air and soil samples from sites surrounding two industrial factories in the Czech Republic.

Karel Chroust; Petr Kuglík; Jiřina Relichová; Ivan Holoubek; Josef Čáslavský; Renata Veselská; Rysková M; Jaroslav Benedík


Chemosphere | 2007

Quantitative structure–activity relationships for toxicity and genotoxicity of halogenated aliphatic compounds: Wing spot test of Drosophila melanogaster

Karel Chroust; Martina Pavlová; Zbyněk Prokop; Jan Mendel; Kateřina Božková; Zdeněk Kubát; Veronika Zajı´čková; Jiří Damborský


Physiological Research | 2008

Mutation Analysis of Candidate Genes SCN1B, KCND3 and ANK2 in Patients with Clinical Diagnosis of Long QT Syndrome

Martina Raudenská; Alexandra Bittnerová; Tomáš Novotný; Alena Floriánová; Karel Chroust; Renata Gaillyová; Bořivoj Semrád; Jitka Kadlecová; Martina Šišáková; Ondřej Toman; Jindřich Špinar


Vnitr̆ní lékar̆ství | 2011

The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)

Krupicka J; Miroslav Souček; Karel Chroust


Archive | 2010

Comparison of survival rates of TNFα antagonists in rheumatoidarthritis, ankylosing spondylitis, juvenile idiopathicarthritis and psoriatic arthritis in Czech national registryATTRA

Karel Pavelka; Závada; Heřman Mann; Karel Chroust; Lucie Burešová; Vencovský

Collaboration


Dive into the Karel Chroust's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge